| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/11/2005 | CN1200698C Use of corneal hardening agent in enzyme orthokeratology |
| 05/11/2005 | CN1200697C Transnasal anticonvulsive compositions and modulated process |
| 05/11/2005 | CN1200690C Pressurised metered dose inhalers |
| 05/11/2005 | CN1200687C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology |
| 05/10/2005 | US6890958 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 05/10/2005 | US6890957 Liquid formulation of metformin |
| 05/10/2005 | US6890945 Administering a imidazo(4,5,1-ij)quinoline compound |
| 05/10/2005 | US6890943 3-acylated pyridoxal derivatives used to treat vitamin B6 deficiency, cardiovascular diseases, melanoma and other related diseases |
| 05/10/2005 | US6890938 Antiinflammatory agents |
| 05/10/2005 | US6890931 Methods of treating disorders with group I mGluR antagonists |
| 05/10/2005 | US6890924 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 05/10/2005 | US6890918 Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890906 Administering a compound which binds to a galectin |
| 05/10/2005 | US6890904 An antiangiogenic, anticancer, and an antiproliferative which inhibits the enzyme fibroblast activation protein-alpha (FAP-alpha); peptides with reactive analog of proline where the COOH is replaced by a boronyl group (B(OH)2); val-boro-pro |
| 05/10/2005 | US6890898 Method of regulating glucose metabolism, and reagents related thereto |
| 05/10/2005 | US6890731 For drug screeing/therapy of diseases; bacteriophages |
| 05/10/2005 | US6890560 Negatively charged amphiphilic block copolymer as drug carrier |
| 05/10/2005 | US6890526 Diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological |
| 05/10/2005 | US6890517 A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide |
| 05/10/2005 | US6890485 High throughput chemical handling system |
| 05/10/2005 | CA2330935C A mutant human hepatitis b viral strain and uses thereof |
| 05/06/2005 | WO2005040174A1 Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation |
| 05/06/2005 | WO2005040091A1 Aminoalkanol derivatives |
| 05/06/2005 | WO2005039640A1 Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
| 05/06/2005 | WO2005039639A2 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| 05/06/2005 | WO2005039638A2 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor |
| 05/06/2005 | WO2005039637A2 Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker |
| 05/06/2005 | WO2005039636A1 Agent for potentiating curing effects-enhancing medicinal substance action |
| 05/06/2005 | WO2005039625A1 Growth hormone secretagogue receptor agonists |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039598A1 Method of treating alcoholic liver disease |
| 05/06/2005 | WO2005039596A1 Silyl phenols for promoting vascular health |
| 05/06/2005 | WO2005039594A1 Combinations comprising ampa receptor antagonists for the treatment of myopia |
| 05/06/2005 | WO2005039593A1 Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain |
| 05/06/2005 | WO2005039587A1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 05/06/2005 | WO2005039579A1 Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| 05/06/2005 | WO2005039577A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain |
| 05/06/2005 | WO2005039576A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions |
| 05/06/2005 | WO2005039566A1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 05/06/2005 | WO2005039557A1 Use of selected amino acid-zinc complexes as anti-malarial |
| 05/06/2005 | WO2005039550A2 Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
| 05/06/2005 | WO2005039545A1 Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |
| 05/06/2005 | WO2005039540A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 05/06/2005 | WO2005039539A1 ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE α-KETOGLUTARATE |
| 05/06/2005 | WO2005039537A1 Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| 05/06/2005 | WO2005039528A2 Composition for the treatment of arthrosis/arthritis, especially for treating joints |
| 05/06/2005 | WO2005039493A2 Herbal composition for weight control |
| 05/06/2005 | WO2005039485A2 Gsk-3 inhibitors and uses thereof |
| 05/06/2005 | WO2005039483A2 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 05/06/2005 | WO2005039320A2 Composition for the activation of the immune system |
| 05/06/2005 | WO2005027895A3 Thyroid hormone analogs and methods of use in angiogenesis |
| 05/06/2005 | WO2005018624A3 Methods of treating copd and pulmonary hypertension |
| 05/06/2005 | WO2004096194A3 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains |
| 05/06/2005 | WO2004094622A3 Extracellular messengers |
| 05/06/2005 | WO2004091495A3 Compositions and methods related to production of erythropoietin |
| 05/06/2005 | WO2004080488A3 Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor |
| 05/06/2005 | WO2004064725A3 Oral compositions and methods for treatment of adverse effects or radiation |
| 05/06/2005 | WO2004062614A3 Carbohydrate conjugates to prevent abuse of controlled substances |
| 05/06/2005 | WO2004047727A3 Compositions and methods for diagnosing and treating mood disorders |
| 05/06/2005 | WO2004032967A8 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity |
| 05/06/2005 | WO2003068746A8 Aryl ureas as kinase inhibitors |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | CA2842308A1 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| 05/06/2005 | CA2543342A1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 05/06/2005 | CA2543338A1 Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
| 05/06/2005 | CA2543197A1 Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| 05/06/2005 | CA2542434A1 Combination of flupirtine and tolperisone or eperisone for the treatment of painful conditions |
| 05/06/2005 | CA2541990A1 Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and l-arginine .alpha.-ketoglutarate |
| 05/06/2005 | CA2539277A1 Aminoalkanol derivatives |
| 05/06/2005 | CA2537224A1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 05/06/2005 | CA2528805A1 Gsk-3 inhibitors and uses thereof |
| 05/06/2005 | CA2526804A1 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096457 Peptide substrates and fusion polypeptide substrates comprising a beta -secretase cleavage site wherein a human Aspartyl protease cleaves the peptide between P1 and P1, the rate of which cleavage is used to identify modulators of Alzeimer's disease, neurofibrillary tangles, gliosis and neuronal loss |
| 05/05/2005 | US20050096395 Norepinephrine-serotonin reuptake inhibitor (NSRI) compound to treat attention deficit/hyperactivity disorder and Tic disorder; NSRI compound has a NE:5-HT reuptake inhibition ratio of between 1:1 and 10:; milnacipran |
| 05/05/2005 | US20050096391 Particulate or in solid dosage forms; a combination of fenofibrate and HMG CoA reductase inhibitor rosuvastatin or a pharmaceutically active salts, upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCrosuvastatin) of between 150 to 12,000 |
| 05/05/2005 | US20050096390 Compositions comprising fenofibrate and pravastatin |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096382 Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| 05/05/2005 | US20050096364 Iminothiazolidinones as inhibitors of HCV replication |
| 05/05/2005 | US20050096344 controlling signal transduction; anticancer agents; antitumor agents; angiogenesis inhibitors; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents; antiischemic agents |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096334 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096307 for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal |
| 05/05/2005 | US20050096304 Method of treating cancer using dithiocarbamate derivatives |
| 05/05/2005 | US20050096303 Cardiovascular protection using anti-aldosteronic progestins |
| 05/05/2005 | US20050096286 Plasmid encoding of fibroblast growth factor as treatment for hypercholesterolemia or diabetes |
| 05/05/2005 | US20050096268 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| 05/05/2005 | US20050096266 Administering trypsin inhibitor and amino acid |
| 05/05/2005 | US20050096257 Administering platelet derived growth factor antagonist and endothelial growth factor antagonist |
| 05/05/2005 | US20050096256 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 05/05/2005 | US20050096253 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 05/05/2005 | US20050095667 Oligomeric lysine-aspartic acid-glutamic acid-leucine amino acid sequence binding protein suppressor; for amplification of immune response to secreted chaperone proteins |
| 05/05/2005 | US20050095663 Via 6-(4-chlorophenyl)-2-(2'-pentyn-4'-ene-1-yl)-3(2H)-pyridazinone for inhibition of delta-9 fatty acid desaturase |
| 05/05/2005 | US20050095304 Composition and method for smoke detoxification |
| 05/05/2005 | US20050095300 Controlled release analgesic suspensions |
| 05/05/2005 | US20050095291 Tamper-resistant oral opioid agonist formulations |